Description

Product Description

CP-EPS8-NLS is a novel therapeutic research peptide that selectively targets EPS8 (Epidermal Growth Factor Receptor Pathway Substrate 8), a critical regulator of oncogenic signaling, actin remodeling, and cellular motility. The peptide incorporates a nuclear localization sequence (NLS) and a cell-penetrating sequence (CP), enhancing its intracellular delivery and nuclear accumulation, which are essential for effective inhibition of EPS8-driven tumorigenesis.

Research has shown that EPS8 plays an essential role in multiple cancers, including acute myeloid leukemia (AML), by interacting with signaling molecules such as Rac and actin cytoskeleton modulators. CP-EPS8-NLS disrupts these molecular interactions, effectively blocking EPS8-dependent cytoskeletal rearrangements and downstream oncogenic signaling cascades, including PI3K/AKT and MAPK/ERK pathways. This results in decreased proliferation, enhanced apoptosis, and reduced tumor invasiveness.

In AML models, CP-EPS8-NLS demonstrates a significant reduction in leukemic cell viability and induces differentiation, suggesting that the EPS8 pathway contributes to leukemogenesis through the maintenance of undifferentiated, proliferative phenotypes. Furthermore, in vivo xenograft studies reveal marked tumor regression and prolonged survival rates, underscoring its potential as a targeted therapeutic peptide.

Structurally, CP-EPS8-NLS is designed for optimal stability and cellular uptake. The presence of positively charged residues enhances its permeability across cellular membranes, while the NLS component directs the peptide to the nucleus, enabling it to modulate nuclear signaling pathways that regulate oncogene transcription and chromatin remodeling. This dual-targeting mechanism provides a synergistic approach for suppressing EPS8-mediated oncogenic programs.

Ongoing research highlights CP-EPS8-NLS as a valuable tool for elucidating EPS8’s role in cancer biology and as a promising candidate for developing peptide-based therapies against AML and other EPS8-overexpressing malignancies.

Product Specifications

Mechanism of Action

CP-EPS8-NLS exerts its anti-leukemic and antitumor effects primarily by inhibiting the EPS8 signaling network. EPS8 is a multifunctional scaffold protein that modulates actin dynamics, EGFR signaling, and cell migration through its interactions with Rac GTPase and the actin cytoskeleton. Overexpression of EPS8 has been correlated with aggressive tumor phenotypes and resistance to apoptosis.

By competitively binding to EPS8-associated proteins, CP-EPS8-NLS prevents the formation of the EPS8–Rac complex, resulting in impaired Rac activation and disruption of actin filament organization. This inhibition attenuates the downstream activation of PI3K/AKT and ERK pathways, both of which are essential for leukemic cell proliferation and survival.

In AML cells, CP-EPS8-NLS interferes with the nuclear translocation of EPS8 and downregulates key transcription factors involved in oncogenic gene expression, such as c-Myc and NF-κB. Moreover, it triggers caspase activation and mitochondrial membrane depolarization, promoting intrinsic apoptosis.

The peptide’s cell-penetrating (CP) component enhances cytoplasmic delivery, while its nuclear localization sequence ensures that it reaches the nuclear compartment to exert direct transcriptional inhibition. This two-pronged targeting strategy not only diminishes EPS8 expression but also reprograms oncogenic gene networks, leading to decreased tumor cell viability and metastatic potential.

Collectively, CP-EPS8-NLS functions as a dual-action peptide that integrates signaling pathway blockade and nuclear modulation, establishing it as a powerful molecular tool for cancer research and anti-AML drug discovery.

Side Effects

In preclinical studies, CP-EPS8-NLS demonstrates low cytotoxicity toward normal hematopoietic cells, with a selectivity index favoring malignant cells over healthy tissues. Mild, transient effects such as cell cycle arrest and reversible mitochondrial stress have been observed at higher concentrations, but no irreversible DNA damage or off-target signaling alterations have been reported.

Due to its targeted mechanism, systemic side effects are minimal compared to small-molecule inhibitors. However, researchers should monitor potential off-target effects related to actin cytoskeleton interference, as EPS8 participates in normal cellular processes such as endocytosis and cell morphology regulation.

Standard safety precautions should be followed when handling CP-EPS8-NLS in laboratory environments. The compound is intended exclusively for in vitro and in vivo experimental studies, not for diagnostic or therapeutic use in humans.

Disclaimer

All information presented is for research and educational purposes only. CP-EPS8-NLS is intended strictly for laboratory use and not for human or veterinary applications.

Keywords

CP-EPS8-NLS, anti-AML peptide, EPS8 inhibitor, leukemia research, xenograft tumor peptide, EPS8 signaling blocker, peptide oncology reagent

Shipping Guarantee

All shipments are handled using validated cold-chain logistics to preserve peptide integrity. Each package is sealed in moisture-proof containers with secondary protective wrapping and continuous temperature monitoring. Products are shipped via express international couriers with full tracking and insurance coverage.

Trade Assurance

We ensure product authenticity, verified ≥99% purity, and compliance with analytical standards (HPLC, MS, and NMR). Each batch is supplied with a Certificate of Analysis (CoA). Our trade assurance policy guarantees replacement or refund for any deviation from listed specifications.